Described herein are heterodimers containing at least one first polypeptide and at least one second polypeptide, wherein the first polypeptide and the second polypeptide meet at an interface, wherein the interface of the first polypeptide contains an engineered protuberance which is positionable in an engineered cavity in the interface of the second polypeptide; and (i) the first polypeptide contains an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; or (ii) the first polypeptide contains an MHC class II β1 domain, an MHC class II β2 domain, or a combination thereof; and the second polypeptide comprises an MHC class II α1 domain, an MHC class II α2 domain, or a combination thereof.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
2.
SYSTEMS AND METHODS FOR DETECTING OCULAR LESIONS IN FUNDUS IMAGES
Methods and systems are described for detecting ocular lesions indicative of an ocular pathology. The methods and systems involve obtaining a fundus image of an eye of a patient, preprocessing the fundus image to obtain a processed fundus image applying a detection model to the processed fundus image to identify whether a lesion is present in the fundus image providing an output based on an output result of the detection model. The detection model is configured for detecting ocular lesions in fundus images and the output is related to a lesion being present in the fundus image.
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
The present disclosure relates generally to the treatment of Fragile X Syndrome using a recombinant fusion polypeptide comprising or consisting of a cell penetrating polypeptide, such as HIS or tat, and a Fragile X Mental Retardation protein (FMRP (298)).
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A biosensor wearable by a user is provided comprising a sensor configured to be retained by a casing, the sensor having a contact surface for contacting the user, the contact surface comprising a concatenated aptamer, the concatenated aptamer configured to bind to a target biomolecule for generating a signal indicating a change in electrical resistance corresponding to a concentration of the target biomolecule.
System and method for correcting GNSS NLOS error using ray-tracing. A processor is in communication with a receiver configured to receive a signal from at least one signal source. A ray-tracing module of the processor performs ray-tracing on a plurality of simulated testing rays that pass through a low-resolution pixel shader image. Then, results of the first ray-tracing process are clustered based on reflection surfaces combination encountered and mirror-based ray-tracing is performed on the clustered results. A best result of the mirror-based ray-tracing process (i.e., a result having the highest signal power) is selected, corresponding to a most likely path between said receiver and the signal source, and is useful for correcting errors in signals received by the signal.
Embodiments of the present invention are directed to a method of synthesizing a nanoparticle, e.g., asphaltene quantum dots ("AQD") and/or asphaltene carbon dots ("ACD"), the method comprising: contacting a source of asphaltene with an organic solvent to form an asphaltene and organic solvent mixture; removing; contacting the asphaltene and organic solvent mixture with an acid to form an acidic mixture; heating the acidic mixture to form an unpurified AQD and/or ACD; removing the acid; and adjusting the pH to form the AQD and/or ACD.
Systems and methods for determining a user's absolute acceleration/deceleration on an Earth based reference frame. Signals from multiple satellites are received and the Doppler rate for each satellite is extracted using baseband signal processing. Then, using each satellite's ephemeris, the acceleration/deceleration and Earth frame position of each satellite is determined. The user's absolute position is then used, along with each satellite's position to calculate direction cosine vector projections for each satellite. The user's absolute acceleration/deceleration is then calculated using the various direction cosine vector projections, the various satellite acceleration/deceleration values, and each satellite's Doppler rates. The resulting absolute acceleration/deceleration can then be used for more accurate navigation solutions.
Multilayer organic electronic devices having an electron transport layer (ETL). The ETL is a film comprising an N-annulated perylene diimide (NPDI) compound having at least one pyrrole N—H bond and at least 1 equivalent of Cs2CO3 with respect to the NPDI compound and the number of pyrrolic N—H bonds in the NPDI compound. The ETL is positioned between the photoactive layer and the top electrode (cathode). Multilayer devices including the ETL are fabricated employing immiscible solvent methods. A method for making the ETL layers is provided which employs an ink formulation in which the NPDI compound is solubilized in a selected polar solvent by addition of at least one equivalent of Cs2CO3 respect to the NPDI compound. Exemplary polar solvents include ethanol, 1-propanol, ethyl acetate and mixtures thereof.
H10K 30/85 - Layers having high electron mobility, e.g. electron-transporting layers or hole-blocking layers
H10K 30/86 - Layers having high hole mobility, e.g. hole-transporting layers or electron-blocking layers
H10K 71/13 - Deposition of organic active material using liquid deposition, e.g. spin coating using printing techniques, e.g. ink-jet printing or screen printing
H10K 85/60 - Organic compounds having low molecular weight
H10K 102/20 - Metallic electrodes, e.g. using a stack of layers
10.
SORBENTS AND METHODS FOR CARBON CAPTURE VIA CALCIUM LOOPING
The present disclosure provides CO2 sorbent materials and methods of producing the same. The method includes: (a) combining calcium, at least one metal, and a fuel in a solvent to form a solution; (b) heating the solution formed in (a) to evaporate the solvent and form a combustion mixture; (c) heating the combustion mixture formed in (b) to combustion, to form a combusted material; and (d) calcinating the combusted material formed in (c) to form the CO2 sorbent. The CO2 sorbent may be used for capturing CO2, such as in a calcium looping process.
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/30 - Processes for preparing, regenerating or reactivating
An MOF film comprising an MOF and an organic scaffold. The MOF is attached to the organic scaffold by hydrogen bonds. The MOF film may be a PCMOF and/or HKUST and may have proton conductive properties. The MOF film may comprise a coordinated metal. The organic scaffold may comprise cellulose material. The MOF film may be free standing without physical support from another material or structure, may be formed into shapes, and may be bent or folded. The MOF film may comprise an MOF and an organic scaffold at different weight ratios.
Methods and cells are provided for electrochemically oxidizing methane to formate, in which methane supplied to an alkaline aqueous anolyte medium comprising hydroperoxyl anions is brought into contact with an oxidation catalyst anode. The oxidation catalyst may include CuFe oxide catalytic centres supported on a nickel substrate. An anodic current supplied to the oxidation catalyst in the anolyte medium electrolytically oxidizes methane to formate.
C25B 11/077 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the compound being a non-noble metal oxide
13.
MICRONEEDLE AND ARRAY AND METHOD OF FABRICATING SAME
A method of fabricating a microneedle is disclosed, including: applying a force to a conductive wire to create a friction weld between the wire and a substrate; extruding the wire and interrupting the wire bonding process; and applying a wire weakening process at a desired microneedle length to cause the wire to break at the desired microneedle length. A microneedle array includes a substrate and a plurality of solid microneedles provided on the substrate. Adjacent microneedles may have different heights and different diameters. The substrate defines a plurality of microfluidic channels each having a channel outlet. the channel outlets provided adjacent the bases of the plurality of solid microneedles to enable drug delivery. The method and array overcome issues with needle stick injuries and needle phobia, and can be used without direct medical supervision, thus reducing healthcare expenditure.
A method of inducing a Type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the Type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene, and an immunogen to which that response is to be enhanced. A mammalian HX compound-adjuvanted vaccine composition that contains an immunogen present in a vaccine-effective amount along with an adjuvant-effective amount of a halogenated xanthene (HX) compound and one or more excipients present at about 0.001% by weight to 10% by weight of the vaccine composition dissolved or dispersed in a pharmaceutically acceptable diluent.
The present application relates to the use of hydroxyphenyl propanoate compounds of Formula (I), (II), (III), (IV) or (V), or pharmaceutically acceptable salts, solvates and/or ester prodrugs thereof, to increase anti-tumour immunity, to compositions comprising them, and their use, for example, in cancer immunotherapy. More particularly, the present application relates to compounds useful in the treatment of diseases, disorders, or conditions treatable by increasing anti-tumour immunity in a cell, such as cancer.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
C07C 59/90 - Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
C07C 229/42 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
16.
CHROMIUM PHOSPHONATE METAL-ORGANIC FRAMEWORKS, PROCESS FOR PREPARING THE SAME AND USES THEREOF
The present application relates to metal-organic frameworks (MOFs). More specifically, the present application relates to process for their preparation and uses thereof. The present application includes a process for preparing a chromium (III) phosphonate metal-organic framework (MOF) comprising: a) dehydrating a hydrogen-bonded metal-organic framework (HMOF) comprising chromium (III) hydrogen bonded to one or more organic polyphosphonate molecule by heating the HMOF at a controlled rate; b) cooling the dehydrated HMOF from a) to provide the MOF.
C07F 11/00 - Compounds containing elements of Groups 6 or 16 of the Periodic Table
B01D 15/08 - Selective adsorption, e.g. chromatography
B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
B01J 20/30 - Processes for preparing, regenerating or reactivating
This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of TR1 cells and/or B cells in an antigen-specific manner and treating diseases and disorders in a subject in need thereof.
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
19.
SNAPSHOT GNSS RECEIVER AND METHOD USING SUPER-LONG COHERENT INTEGRATION AND FRACTIONAL FOURIER TRANSFORM
Snapshot receiver that comprises a correlator module for correlating incoming GNSS signals and a transform module that transforms resulting correlated outputs using a Fractional Fourier Transform (FrFT) process, to thereby compensate for weak and dynamic signals. The output of the transform module is an estimated Doppler rate with high accuracy. The estimated Doppler rate is passed to a super-resolution-measurement (SRM) module, which outputs error values of the estimated Doppler rate and a pseudorange (measured distance-to-satellite) via a phase dead reckoning (DR) calculation for the snapshot receiver. The pseudorange and error values are passed to a navigator module that determines position information based on those inputs. In some embodiments, the SRM module comprises a maximum likelihood estimator (MLE).
G01S 19/24 - Acquisition or tracking of signals transmitted by the system
G01S 19/29 - Acquisition or tracking of signals transmitted by the system carrier related
G01S 19/30 - Acquisition or tracking of signals transmitted by the system code related
G01S 19/37 - Hardware or software details of the signal processing chain
G01S 19/39 - Determining a navigation solution using signals transmitted by a satellite radio beacon positioning system the satellite radio beacon positioning system transmitting time-stamped messages, e.g. GPS [Global Positioning System], GLONASS [Global Orbiting Navigation Satellite System] or GALILEO
Apparatuses and methods are disclosed for gathering biological samples from medium to large terrestrial mammals, such as gathering a blood sample from an animal. A remote blood collection apparatus, or dart, includes a fluid collection reservoir maintaining a vacuum, and one or more sharpened tubular ends, which may be one or more needles. In response to the apparatus being driven into an animal, a continuous passage is created from the fluid collection reservoir through the one or more sharpened tubular ends. The apparatus is configured to extract, using the vacuum in the fluid collection reservoir and from the animal, fluid into the fluid collection reservoir from the animal. The apparatus provides advantages over known blood collection techniques, as well as known biopsy needles that take a sample of core flesh along with blood and may result in inaccurate sample analysis.
A61B 5/153 - Devices for taking samples of blood specially adapted for taking samples of venous or arterial blood, e.g. by syringes
F42B 12/54 - Projectiles, missiles or mines characterised by the warhead, the intended effect, or the material characterised by the warhead or the intended effect for dispensing materialsProjectiles, missiles or mines characterised by the warhead, the intended effect, or the material characterised by the warhead or the intended effect for producing chemical or physical reactionProjectiles, missiles or mines characterised by the warhead, the intended effect, or the material characterised by the warhead or the intended effect for signalling for dispensing gases, vapours, powders or chemically-reactive substances by implantation, e.g. hypodermic projectiles
21.
DETECTING A DINUCLEOTIDE SEQUENCE IN A TARGET POLYNUCLEOTIDE
The present disclosure relates to improvements in the Dinucleotide signaTurE CapTure (DTECT) method. The improved detection of a dinucleotide sequence in a target polynucleotide generally involves the steps of Acu1 digestion, heat inactivation and ligation to unique adaptors containing overhangs of two bases complementary to the dinucleotide signature.
A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure is directed to compounds that may selectively inhibit Death Associated Protein Kinases (DAPKs) as well as PIM kinases. The compounds can be used in methods of treating various disorders, including cancers.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Disclosed herein are hydrogel precursor solutions, hydrogels, and methods of preparation and uses of the same. The hydrogels may be gelled at room temperature, in the absence of added light or heat, to yield ultra-strong hydrogel fibers suitable for load-bearing applications, or as adhesives or coatings. The hydrogels may include a polymerized polymer containing acrylic acid, additional acrylic acid, an organic acid such as citric acid, and an oxidizing agent such as a persulfate salt. Silver-lignin nanoparticle suspensions may be used to initiate a free radical oxidative decarboxylation reaction in the disclosed compositions. Hydrogels may be prepared from such compositions through incubation leading to gelling. The gelled hydrogels may be stretched or spun into hydrogel fibers having desirable mechanical properties, such as strength, stretchability, and adhesion.
C08L 33/26 - Homopolymers or copolymers of acrylamide or methacrylamide
A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
Described herein, is an isolated cell comprising a recombinant T cell receptor (TCR) and a TCR-pathway-dependent reporter, wherein the recombinant T cell receptor is specific for a disease-relevant antigen bound to an MHC molecule. Also described are methods of use for the isolated cell as an assay to determine the function or potency of a peptide-major histocompatibility complex (pMHC) coupled to a nanoparticle (pMHC-NP) that can be used as a medicine for treating an autoimmune disease or cancer.
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Disclosed is a method for treatment of a subject having, or suspected of having, a cancer, in particular colorectal cancer, using an immune checkpoint inhibitor in combination with one or more bacteria selected from Bifidobacterium pseudolongum, Lactobacillus johnsonii, and Olsenella species, wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody or an anti-PD-1 antibody, wherein antibiotic therapy may precede the use of the immune checkpoint inhibitor and the one or more bacteria.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/708 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (Switzerland)
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV) (Switzerland)
UTI LIMITED PARTNERSHIP (Canada)
Inventor
Courtine, Grègoire
Bloch, Jocelyne
Squair, Jordan
Phillips, Aaron
Mahe, Loïs
Abstract
The present invention relates to a neuromodulation/neurostimulation system (10) for stimulating at least one neuronal circuitry responsible for micturition control in a mammal with bladder disfunction, especially for bladder relaxation and/or for bladder voiding, said system (10) comprising: - at least one control unit (12), and - at least one stimulation unit (14), configured and arranged to provide electrical stimulation to the spinal cord of said mammal. Further, the present invention relates to the use of the neuromodulation/neurostimulation system (10).
Provided are glycoprotein NMB (GPNMB)-binding chimeric antigen receptors (CARs). In some embodiments, a CAR of the present disclosure comprises an extracellular GPNMB-binding domain (e.g., a single chain antibody, such as an scFv), a transmembrane domain, and one or more intracellular signaling domains. Nucleic acids and expression constructs encoding such CARs are also provided. Also provided are cells (e.g., immune cells, such as T cells) comprising the nucleic acids and expression constructs. Aspects of the present disclosure further include compositions comprising a population of such cells expressing the GPNMB-binding CAR on their surface, as well as methods of administering such compositions to treat a condition associated with GPNMB expression and/or activity in a subject in need thereof. Non-limiting examples of conditions associated with GPNMB expression and/or activity include cancer (e.g., sarcomas, such as soft tissue sarcomas), neurodegenerative diseases, and the like.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/62 - DNA sequences coding for fusion proteins
30.
MICROGELS, METHODS, COMPOSITIONS, AND USES THEREOF
A hybrid microgel, comprising a thermoresponsive polymer, and a polysaccharide comprising amorphous domains, the thermoresponsive polymer being grafted to the polysaccharide; methods of making the hybrid microgel, and compositions useful for tissue engineering comprising the hybrid microgel.
C08L 51/02 - Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCompositions of derivatives of such polymers grafted on to polysaccharides
C08J 3/02 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
C09K 8/588 - Compositions for enhanced recovery methods for obtaining hydrocarbons, i.e. for improving the mobility of the oil, e.g. displacing fluids characterised by the use of specific polymers
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
31.
TRANSITIONAL TAPPING ATOMIC FORCE MICROSCOPY FOR HIGH-RESOLUTION IMAGING
Electrodes useful for membrane- free electrode assemblies, membrane-free electrode assemblies, methods of making, and uses thereof. The electrodes comprise a catalyst layer; and a solid polymer electrolyte layer for ion-conduction deposited on the catalyst layer. The solid polymer electrolyte layer is deposited on a catalyst layer as an ionomer resin solution and forms an ion conducting layer thereby eliminating the need for a stand-alone membrane that is introduced as a separate component into electrode assemblies.
C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
C25B 1/04 - Hydrogen or oxygen by electrolysis of water
Institute of Geology and Geophysics, Chinese Academy of Sciences (China)
UTI LIMITED PARTNERSHIP (Canada)
Inventor
Cao, Changqian
Bryant, Steven L.
Abstract
Polymer-coated nanoparticles, a composite nano-emulsion and a macro-emulsion are provided. In the polymer-coated nanoparticles, the polymer self-assembles into a cage-shaped structure to coat the nanoparticles; and the nanoparticles are iron-containing metal oxides. The polymer-coated nanoparticle shell provided by the present invention can be used as a stabilizer to prepare a composite nano-emulsion, and furthermore, a stable macro-emulsion can be prepared at an extremely low concentration. The problems that high-concentration surfactants and solid particles are required to stay on an oil-water interface in macro-emulsion synthesis, and surface tension is reduced to stabilize large oil drops are overcome.
C08K 9/08 - Ingredients agglomerated by treatment with a binding agent
C08J 3/03 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
34.
Halogenated xanthene composition and method for treating hematologic cancers
4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/21 - Esters, e.g. nitroglycerine, selenocyanates
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
35.
Compositions and methods of use for treatment or improvement of the condition and appearance of skin
Compositions, formulations and methods of use thereof for treating, preventing and improving the condition and aesthetic appearance of skin are described. Compositions, formulations and methods of use thereof for treatment of dermis wounds, aged dermis, diseased dermis or damaged dermis are also described. The present compositions and formulations comprise a peptide with an amino acid sequence of QHREDGS (SEQ ID NO: 1) and methods of use thereof.
A method is provided for producing a fiber-reinforced composite in a fused filament fabrication (FFF) process for additive manufacturing, including: depositing, using a deposition tool, a composite raster by extruding the fiber-reinforced composite onto a deposition surface; miming a consolidation tool having a heated or heat-inducing non-rolling tip over the deposited composite raster, to apply a shear force to reduce fiber waviness; and applying, using the consolidation tool, heat and a compressive force concurrent with the application of the shear force to pressurize the composite raster and reduce void content. The process reduces porosity while at the same time, increasing fiber straightness in composite material deposited via FFF, increasing reinforcement-matrix adhesion, and matrix cohesion. A separate, independently controlled tool runs over previously deposited material using an interior point-out technique. The method reduces void contents of high fiber volume composites to a level suitable for the production of structural composite parts for aerospace applications, without requiring post-consolidation operations.
B29C 64/194 - Processes of additive manufacturing involving additional operations performed on the added layers, e.g. smoothing, grinding or thickness control during lay-up
B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
The present disclosure generally relates to a method of producing a film for use with de-icing and EMI shielding. The film is a multilayer film on a substrate comprising a layer of PEFOT:PSS, a AgNW layer and a second PEDOT:PSS layer. The film is produced by a simple low-cost fabrication method and does not require vacuum, pressing or high temperature processing.
B32B 37/24 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the properties of the layers with at least one layer not being coherent before laminating, e.g. made up from granular material sprinkled onto a substrate
H05B 3/84 - Heating arrangements specially adapted for transparent or reflecting areas, e.g. for demisting or de-icing windows, mirrors or vehicle windshields
B32B 15/02 - Layered products essentially comprising metal in a form other than a sheet, e.g. wire, particles
38.
METHODS OF CHANGING ION CONCENTRATIONS IN SURFACE WATER, AND SYSTEMS THEREOF
C02F 1/46 - Treatment of water, waste water, or sewage by electrochemical methods
C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes
G01D 5/00 - Mechanical means for transferring the output of a sensing memberMeans for converting the output of a sensing member to another variable where the form or nature of the sensing member does not constrain the means for convertingTransducers not specially adapted for a specific variable
G01L 9/00 - Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by electric or magnetic pressure-sensitive elementsTransmitting or indicating the displacement of mechanical pressure-sensitive elements, used to measure the steady or quasi-steady pressure of a fluid or fluent solid material, by electric or magnetic means
G01M 15/14 - Testing gas-turbine engines or jet-propulsion engines
G12B 1/00 - Sensitive elements capable of producing movement or displacement for purposes not limited to measurementAssociated transmission mechanisms therefor
Methods are disclosed for dispersing nanoparticles in solvents, involving the use of a cationic species and an anionic species, where at least one of the ionic species is soluble in the nonpolar solvent and the other ionic species has a relatively strong affinity for the surface of the nanoparticles. The cationic species and the anionic species together form a cluster of ion pairs shielding the nanoparticles and enhancing their dispersibility in the nonpolar solvent.
The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells using biocompatible bioabsorbable nanospheres. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
43.
SYSTEMS AND METHODS FOR PREDICTING CARDIOTOXICITY OF MOLECULAR PARAMETERS OF A COMPOUND BASED ON MACHINE LEARNING ALGORITHMS
Systems and methods are provided for predicting cardiotoxicity of molecular parameters of a compound. A computer can provide as input to a machine learning algorithm the molecular parameters of the compound. The molecular parameters can include at least structural information about the compound. The machine learning algorithm can have been trained using respective molecular parameters of compounds known to have cardiotoxicity and of compounds known not to have cardiotoxicity. The computer can receive as output from the machine learning algorithm a representation of the predicted cardiotoxicity of each molecular parameter of at least a subset of the molecular parameters of the compound.
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
G16B 35/00 - ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (Switzerland)
UTI LIMITED PARTNERSHIP (Canada)
REGENTS OF THE UNIVERSITY OF MINNESOTA (USA)
Inventor
Courtine, Grégoire
Phillips, Aaron
Sqair, Jordan
Darrow, David
Abstract
An implantable blood pressure monitor has two or more elements configured to wrap at least part way around a blood vessel. Changes in pressure within the blood vessel may be sensed by detecting movements of the elements or forces applied to the elements. A blood pressure monitor may be implanted without surgery. The blood pressure monitor may transmit real time blood pressure information to a receiver by wireless data transmission.
A method of preparing a metal oxide-supported catalyst. The method may involve high-energy ball milling a coke-based material and metal oxide nanoparticles; and comminuting and dispersing the metal oxide nanoparticles on the coke-based material; to form the metal oxide-supported catalyst.
Described herein is a method of determining the risk of a human subject with congenital BAV having BAV-associated aortopathy or developing BAV-associated aortopathy, comprising: obtaining a cell free DNA (cfDNA) sample from the subject, measuring the level of methylation of a methylation marker that is associated with BAV-associated aortopathy in the cfDNA sample, optionally comparing the level of methylation of the methylation maker in the sample of the subject with a comparator control, wherein when the methylation marker is hypo- or hypermethylated the subject as being at risk of developing BAV-associated aortopathy.
The present disclosure relates generally to the treatment of Fragile X Syndrome using a recombinant fusion polypeptide comprising or consisting of a cell penetrating polypeptide, such as HIS or tat, and a Fragile X Mental Retardation protein (FMRP (298)).
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
22 concentration in a gas supplied for breathing by a patient in response to an output signal from a sensor that monitors one or more desired outcomes. Example applications of the present technology include treating spinal cord injury, traumatic brain injury, and cardiac condition or event.
System and method for geo-positioning using a plurality of chained reference stations. A user station receives station-generated correction information—that is, SSR corrections that generated by a single station and unique to that reference station—and positioning information from the specific reference station. A user-positioning module of the user station processes the received positioning information, as well as the reference station's station-specific corrections, to determine the user station's location. In some embodiments, the user station receives positioning and unique correction information from multiple reference stations. The user-positioning module then fuses the received information to determine the user station's location. Additional reference stations can be added to the reference station network by propagation. The reference station's position is known to a predetermined degree of precision.
G01S 19/07 - Cooperating elementsInteraction or communication between different cooperating elements or between cooperating elements and receivers providing data for correcting measured positioning data, e.g. DGPS [differential GPS] or ionosphere corrections
51.
AORTA-SPECIFIC DNA METHYLATION PATTERNS IN CELL-FREE DNA FROM PATIENTS WITH BICUSPID AORTIC VALVE-ASSOCIATED AORTOPATHY
Described herein is a method of determining the risk of a human subject with congenital BAV having BAV- associated aortopathy or developing BAV- associated aortopathy, comprising: obtaining a cell free DNA (cfDNA) sample from the subject, measuring the level of methylation of a methylation marker that is associated with BAV- associated aortopathy in the cfDNA sample, optionally comparing the level of methylation of the methylation maker in the sample of the subject with a comparator control, wherein when the methylation marker is hypo- or hypermethylated the subject as being at risk of developing BAV- associated aortopathy.
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
52.
ELECTRONICALLY ACTIVE, SOLVENT RESISTANT ORGANIC FILMS PROCESSED FROM ALCOHOL OR AQUEOUS MEDIA
Thin films of organic semiconducting material comprising perylene diimide small molecules with pyrrolic N—H bonds. Films are prepared using green solvents including water and alcohols. The films can be solvent-resistant and generally range in thickness from 10 to 1000 nm. Perylene diimide molecules are dissolved in solvent by addition of a base to polarize the pyrrolic N—H bond believed to generate an ionic salt in alcohol or aqueous solution. Devices containing such films are provided. Methods of making films and methods of using films in OPV device applications and in amine sensors are provided.
H10K 85/60 - Organic compounds having low molecular weight
G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
In one aspect, there is a provided a method of treating pain in a subject in need thereof comprising administering to the subject an anaplastic lymphoma kinase (ALK) inhibitor. In one aspect, there is a provided a method of treating pain in a subject in need thereof comprising administering to the subject an ALKAL2 inhibitor.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
54.
ENCRYPTION/DECRYPTION USING KEY ENCAPSULATION/DECAPSULATION
Systems and methods relating to the encryption and decryption of messages to be sent through a communications link. The system and method use a random data source that produces a joint distribution at the receive and transmit sides, along with a trusted random sampler that produces correlated random samples from the random data source to be used at the send and receive sides. At the transmit side, the correlated random sample is used to generate a symmetric key as well as a ciphertext. The symmetric key is then used to encrypt the message. The ciphertext is transmitted, along with the encrypted message, to the receive side. The receive side then uses the ciphertext, along with its own correlated random sample, to recover the symmetric key. The symmetric key is then used to decrypt the encrypted message.
Systems and methods relating to the encryption and decryption of messages to be sent through a communications link. The system and method use a random data source that produces a joint distribution at the receive and transmit sides, along with a trusted random sampler that produces correlated random samples from the random data source to be used at the send and receive sides. At the transmit side, the correlated random sample is used to generate a symmetric key as well as a ciphertext. The symmetric key is then used to encrypt the message. The ciphertext is transmitted, along with the encrypted message, to the receive side. The receive side then uses the ciphertext, along with its own correlated random sample, to recover the symmetric key. The symmetric key is then used to decrypt the encrypted message.
A method of fabricating a microneedle is disclosed, including: applying a force to a conductive wire to create a friction weld between the wire and a substrate; extruding the wire and interrupting the wire bonding process; and applying a wire weakening process at a desired microneedle length to cause the wire to break at the desired microneedle length. A microneedle array includes a substrate and a plurality of solid microneedles provided on the substrate. Adjacent microneedles may have different heights and different diameters. The substrate defines a plurality of microfluidic channels each having a channel outlet, the channel outlets provided adjacent the bases of the plurality of solid microneedles to enable drug delivery.The method and array overcome issues with needle stick injuries and needle phobia, and can be used without direct medical supervision, thus reducing healthcare expenditure.
A method of fabricating a microneedle is disclosed, including: applying a force to a conductive wire to create a friction weld between the wire and a substrate; extruding the wire and interrupting the wire bonding process; and applying a wire weakening process at a desired microneedle length to cause the wire to break at the desired microneedle length. A microneedle array includes a substrate and a plurality of solid microneedles provided on the substrate. Adjacent microneedles may have different heights and different diameters. The substrate defines a plurality of microfluidic channels each having a channel outlet, the channel outlets provided adjacent the bases of the plurality of solid microneedles to enable drug delivery.The method and array overcome issues with needle stick injuries and needle phobia, and can be used without direct medical supervision, thus reducing healthcare expenditure.
Nanoflocculants are provided that are comprised of nanoparticles of titanomagnetite having anionic surface moieties associated with electrostatically bound polymerized chains of cationic polyacrylamide, further comprising lauryl sulfate moieties adsorbed to the surface of nanoparticles of the titanomagnetite nanoparticles and/or adsorbed to the bound cationic polyacrylamide polymers. These nanoflocculants combine the dual functionalities of the polyacrylamide/lauryl sulfate moieties, as well as the surface activity of titanomagnetite nanomaterials. Process are provided for making and using the disclosed nanoflocculants, including uses for flocculating intimate aqueous dispersions of solids and bitumen.
A method of inducing a Type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the Type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene, and an immunogen to which that response is to be enhanced. A mammalian HX compound-adjuvanted vaccine composition that contains an immunogen present in a vaccine-effective amount along with an adjuvant-effective amount of a halogenated xanthene (HX) compound and one or more excipients present at about 0.001% by weight to 10% by weight of the vaccine composition dissolved or dispersed in a pharmaceutically acceptable diluent.
The present disclosure provides CO2 sorbent materials and methods of producing the same. The method includes: (a) combining calcium, at least one metal, and a fuel in a solvent to form a solution; (b) heating the solution formed in (a) to evaporate the solvent and form a combustion mixture; (c) heating the combustion mixture formed in (b) to combustion, to form a combusted material; and (d) calcinating the combusted material formed in (c) to form the CO2 sorbent. The CO2 sorbent may be used for capturing CO2, such as in a calcium looping process.
B01J 20/30 - Processes for preparing, regenerating or reactivating
B01J 20/04 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
62.
SORBENTS AND METHODS FOR CARBON CAPTURE VIA CALCIUM LOOPING
The present disclosure provides CO2 sorbent materials and methods of producing the same. The method includes: (a) combining calcium, at least one metal, and a fuel in a solvent to form a solution; (b) heating the solution formed in (a) to evaporate the solvent and form a combustion mixture; (c) heating the combustion mixture formed in (b) to combustion, to form a combusted material; and (d) calcinating the combusted material formed in (c) to form the CO2 sorbent. The CO2 sorbent may be used for capturing CO2, such as in a calcium looping process.
B01J 20/30 - Processes for preparing, regenerating or reactivating
B01J 20/04 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
63.
Encryption/decryption using key encapsulation/decapsulation
Systems and methods relating to the encryption and decryption of messages to be sent through a communications link. The system and method uses a random data source at the receive and transmit sides, along with a trusted random sampler that produces correlated random samples from the random data source to be used at the send and receive sides. At the transmit side, the correlated random sample is used to generate a symmetric key as well as a ciphertext. The symmetric key is then used to encrypt the message. The ciphertext is transmitted, along with the encrypted message, to the receive side. The receive side then uses the ciphertext, along with its own correlated random sample, to recover the symmetric key. The symmetric key is then used to decrypt the encrypted message.
H04L 9/06 - Arrangements for secret or secure communicationsNetwork security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems
Systems and methods for affecting spin qubits. In a resonator, an optical field is generated using photons. The optical field causes a stress field to form in the resonator as portions of the resonator oscillates. These oscillations, tunable using lasers and/or injection locking, drive spin transitions to thereby affect the population of specific NV spin qubits present in the resonator.
G06N 10/00 - Quantum computing, i.e. information processing based on quantum-mechanical phenomena
G06F 15/00 - Digital computers in generalData processing equipment in general
G02F 1/00 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics
65.
PERYLENE DIIMIDE CATHODE INTERLAYER FOR ORGANIC PHOTOVOLTAICS
Multilayer organic electronic devices having an electron transport layer (ETL). The ETL is a film comprising an N-annulated perylene diimide (NPDI) compound having at least one pyrrole N-H bond and at least 1 equivalent of Cs2CO3 with respect to the NPDI compound and the number of pyrrolic N-H bonds in the NPDI compound. The ETL is positioned between the photoactive layer and the top electrode (cathode). Multilayer devices including the ETL are fabricated employing immiscible solvent methods. A method for making the ETL layers is provided which employs an ink formulation in which the NPDI compound is solubilized in a selected polar solvent by addition of at least one equivalent of Cs2CO3 respect to the NPDI compound. Exemplary polar solvents include ethanol, 1-propanol, ethyl acetate and mixtures thereof.
Methods and cells are provided for electrochemically oxidizing methane to formate, in which methane supplied to an alkaline aqueous anolyte medium comprising hydroperoxyl anions is brought into contact with an oxidation catalyst anode. The oxidation catalyst may include CuFe oxide catalytic centres supported on a nickel substrate. An anodic current supplied to the oxidation catalyst in the anolyte medium electrolytically oxidizes methane to formate.
C25B 11/077 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the compound being a non-noble metal oxide
C07C 51/285 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation with peroxy-compounds
68.
MULTI-METAL ELECTROCATALYTIC SYSTEM FOR METHANE OXIDATION
C25B 11/077 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the compound being a non-noble metal oxide
An MOF film comprising an MOF and an organic scaffold. The MOF is attached to the organic scaffold by hydrogen bonds. The MOF film may be a PCMOF and/or HKUST and may have proton conductive properties. The MOF film may comprise a coordinated metal. The organic scaffold may comprise cellulose material. The MOF film may be free standing without physical support from another material or structure, may be formed into shapes, and may be bent or folded. The MOF film may comprise an MOF and an organic scaffold at different weight ratios.
An MOF film comprising an MOF and an organic scaffold. The MOF is attached to the organic scaffold by hydrogen bonds. The MOF film may be a PCMOF and/or HKUST and may have proton conductive properties. The MOF film may comprise a coordinated metal. The organic scaffold may comprise cellulose material. The MOF film may be free standing without physical support from another material or structure, may be formed into shapes, and may be bent or folded. The MOF film may comprise an MOF and an organic scaffold at different weight ratios.
C08L 85/00 - Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbonCompositions of derivatives of such polymers
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (Canada)
Inventor
Winston, Brent
Banoei, Mohammad Mehdi
Wishart, David
Abstract
The present disclosure provides a method of determining a likelihood of a favorable or unfavorable outcome, such as death or a Glasgow Outcome Scale Extended (GOSE) score ≤ 4, in a subject having severe traumatic brain injury (sTBI). The method involves quantitative assessment of multiple metabolites shortly after the injury, such as on day 1 and/or day 4 for changes indicative of outcome. Quantitative mass spectrometry (MS) or proton (1H) nuclear magnetic resonance spectroscopy (NMR) may be used to assess multiple metabolites within a single blood sample for comparison with a control.
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (Canada)
Inventor
Winston, Brent
Banoei, Mohammad Mehdi
Wishart, David
Abstract
The present disclosure provides a method of determining a likelihood of a favorable or unfavorable outcome, such as death or a Glasgow Outcome Scale Extended (GOSE) score ? 4, in a subject having severe traumatic brain injury (sTBI). The method involves quantitative assessment of multiple metabolites shortly after the injury, such as on day 1 and/or day 4 for changes indicative of outcome. Quantitative mass spectrometry (MS) or proton (1H) nuclear magnetic resonance spectroscopy (NMR) may be used to assess multiple metabolites within a single blood sample for comparison with a control.
A sulfur cathode generated at least in part by in situ electrochemical pulverization of a metallic sulfide compound is provided. The in situ generated sulfur cathode suppresses the unfavorable process of polysulfide shuttling to provide enhanced sulfur cathode performance and is envisioned for use in Li—S, Na—S, K—S, Ca—S, Mg—S or Al—S batteries used to support rechargeable electronic devices and electric vehicles.
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
A fluid discharger and applicator device for uniform distribution or application of the fluid for treating the skin or any surface is disclosed. The fluid discharger and applicator device comprises a handle and an applicator comprising a flexible application head able to absorb fluid and an application head holder for holding the application head. The handle of the fluid discharger and applicator device is defined with a cavity to store a fluid, and the application fluid is able to enter the application head so as to be applied (or application) on skin of a user.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
76.
DETECTING A DINUCLEOTIDE SEQUENCE IN A TARGET POLYNUCLEOTIDE
The present disclosure relates to improvements in the Dinucleotide signaTurE CapTure (DTECT) method. The improved detection of a dinucleotide sequence in a target polynucleotide generally involves the steps of Acul digestion, heat inactivation and ligation to unique adaptors containing overhangs of two bases complementary to the dinucleotide signature.
Provided are peptide-MHC class I and class II molecules having improved stability and high potency, and that can be produced in high yield. Also provided are receptor-signaling nanoparticles comprising the improved peptide-MHC molecules.
A61K 39/385 - Haptens or antigens, bound to carriers
C07K 14/74 - Major histocompatibility complex [MHC]
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A battery cell having an internal pressure, the battery cell including a first electrode, a second electrode, an electrolyte, a separator, and a conductive spacer having a rigid body and being coupled to the first electrode, the spacer being dimensioned to occupy an interior of the battery cell and increase the internal pressure of the battery cell for increasing a compression acting on the first electrode; the electrolyte for forming a solid-electrolyte interphase (SEI) in a battery cell having a lithium based chemistry, comprising: a carbonate based electrolyte, the carbonate based electrolyte for diluting a solute and a solvent having high solubility for lithium ions and film-additives; the solvent being selected for disassociating the film-additives and for forming a contact ion pair with an anion and the lithium ions.
H01M 50/474 - Spacing elements inside cells other than separators, membranes or diaphragmsManufacturing processes thereof characterised by their position inside the cells
H01M 10/056 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes
H01M 50/477 - Spacing elements inside cells other than separators, membranes or diaphragmsManufacturing processes thereof characterised by their shape
A battery cell having an internal pressure, the battery cell including a first electrode, a second electrode, an electrolyte, a separator, and a conductive spacer having a rigid body and being coupled to the first electrode, the spacer being dimensioned to occupy an interior of the battery cell and increase the internal pressure of the battery cell for increasing a compression acting on the first electrode; the electrolyte for forming a solid-electrolyte interphase (SEI) in a battery cell having a lithium based chemistry, comprising: a carbonate based electrolyte, the carbonate based electrolyte for diluting a solute and a solvent having high solubility for lithium ions and film-additives; the solvent being selected for disassociating the film-additives and for forming a contact ion pair with an anion and the lithium ions.
H01M 50/474 - Spacing elements inside cells other than separators, membranes or diaphragmsManufacturing processes thereof characterised by their position inside the cells
H01M 10/056 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes
H01M 50/477 - Spacing elements inside cells other than separators, membranes or diaphragmsManufacturing processes thereof characterised by their shape
Disclosed herein are hydrogel precursor solutions, hydrogels, and methods of preparation and uses of the same. The hydrogels may be gelled at room temperature, in the absence of added light or heat, to yield ultra-strong hydrogel fibers suitable for load-bearing applications, or as adhesives or coatings. The hydrogels may include a polymerized polymer containing acrylic acid, additional acrylic acid, an organic acid such as citric acid, and an oxidizing agent such as a persulfate salt. Silver-lignin nanoparticle suspensions may be used to initiate a free radical oxidative decarboxylation reaction in the disclosed compositions. Hydrogels may be prepared from such compositions through incubation leading to gelling. The gelled hydrogels may be stretched or spun into hydrogel fibers having desirable mechanical properties, such as strength, stretchability, and adhesion.
A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present disclosure relates generally to fluorinated glucosamine analogs and uses thereof, including analogs of N-acetyl glucosamine fluorinated at 4- and/or 6-position(s) and derivatives of xylose at anomeric position for the treatment of a neurological disease, such as multiple sclerosis; inflammation; cancer; central nervous system injury; or conditions associated with up-regulation of an extracellular matrix, such as chondroitin sulfate proteoglycans.
A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.
In an aspect disclosed herein are systems and method for assessing induced seismicity risk for a structural corridor, comprising identifying a spatial extent of the structural corridor; generating a Fault Slip Potential (FSP) parameter distribution associated with the spatial extent of the structural corridor; generating a plurality of realizations based on the FSP parameter distribution, each realization corresponding to a slip-tendency determined using randomly selected values of the FSP parameter distribution, and determining a slip likelihood for the spatial extent of the structural corridor based on the plurality of realizations as a function of an operational parameter for an operation associated with the spatial extent of the structural corridor.
Apparatus and methodologies are provided for determining whether an individual is likely to have an injury, and the likelihood of recovery following the injury, involving determining a threshold reference value for at least one target biomarker, or a combination/pattern of biomarkers, obtaining at least one biological sample from the individual and measuring the concentration of the at least one of the target biomarkers in the sample, and comparing the measured concentrations of the at least one target biomarkers to the threshold reference value to determine whether a change in concentration of the at least one biomarker, or the combination/pattern of biomarkers, has occurred, wherein the change is indicative of the injury, the type of injury, and/or the likelihood of recovery from the injury.
Apparatus and methodologies are provided for determining whether an individual is likely to have an injury, and the likelihood of recovery following the injury, involving determining a threshold reference value for at least one target biomarker, or a combination/pattern of biomarkers, obtaining at least one biological sample from the individual and measuring the concentration of the at least one of the target biomarkers in the sample, and comparing the measured concentrations of the at least one target biomarkers to the threshold reference value to determine whether a change in concentration of the at least one biomarker, or the combination/pattern of biomarkers, has occurred, wherein the change is indicative of the injury, the type of injury, and/or the likelihood of recovery from the injury.
A method of inducing a Type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the Type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene, and an immunogen to which that response is to be enhanced. A mammalian HX compound-adjuvanted vaccine composition that contains an immunogen present in a vaccine-effective amount along with an adjuvant-effective amount of a halogenated xanthene (HX) compound and one or more excipients present at about 0.001% by weight to 10% by weight of the vaccine composition dissolved or dispersed in a pharmaceutically acceptable diluent.
There is provided an atomic force microscopy tapping method for imaging a surface of a sample, the method comprising, the method comprising: determining and setting a free amplitude (Ao) of a cantilever of an atomic force microscope (AFM); determining and setting an operational tapping amplitude (A) of the cantilever based on the free amplitude (Ao); initializing and setting a steady-state timescale (Tc) of the cantilever interacting with the surface of the sample to be imaged; determining an average deformation amplitude (Aa) relative to the operational tapping amplitude (A), the average deformation amplitude (Aa) resulting from the cantilever tapping and deforming the surface of the sample; optimizing the steady- state timescale (Tc) to correspond with a relaxation timescale (Tsurt) of the surface following deformation by the cantilever by setting the condition of reaching the set operational tapping amplitude (A) when the average deformation amplitude (Aa) ≠ 0; scanning the surface of the sample by tapping the surface with the cantilever; and collecting imaging parameters for generating an image of the surface.
There is provided an atomic force microscopy tapping method for imaging a surface of a sample, the method comprising, the method comprising: determining and setting a free amplitude (Ao) of a cantilever of an atomic force microscope (AFM); determining and setting an operational tapping amplitude (A) of the cantilever based on the free amplitude (Ao); initializing and setting a steady-state timescale (Tc) of the cantilever interacting with the surface of the sample to be imaged; determining an average deformation amplitude (Aa) relative to the operational tapping amplitude (A), the average deformation amplitude (Aa) resulting from the cantilever tapping and deforming the surface of the sample; optimizing the steady- state timescale (Tc) to correspond with a relaxation timescale (Tsurt) of the surface following deformation by the cantilever by setting the condition of reaching the set operational tapping amplitude (A) when the average deformation amplitude (Aa) ? 0; scanning the surface of the sample by tapping the surface with the cantilever; and collecting imaging parameters for generating an image of the surface.
Methods of forming dispersible ferroelectric nanoparticles, including polyether-ylated barium titanate nanoparticles. Uses of the dispersible ferroelectric nanoparticles, including as a ferroelectric tracer material, optionally for detecting a presence and/or measuring a distribution of an oil or a hydrocarbon in a subsurface formation and/or flowback fluid. Compositions and methods involving an oil or hydrocarbon recovery fluid and the dispersible ferroelectric nanoparticles for detecting a presence, measuring a distribution, or both of an oil or a hydrocarbon in a subsurface formation and/or flowback fluid.
Provided are polymer-coated nanoparticles, a composite nano-emulsion, and a macro-emulsion. In the polymer-coated nanoparticles, a polymer is self-assembled into a cage structure to coat nanoparticles, wherein the nanoparticles are made of an iron-containing metal oxide. The polymer-coated nano-particle shell provided in the present invention can be used as a stabilizer to prepare a composite nano-emulsion, and a stable macro-emulsion can be further prepared at an extremely low concentration. The problems of a high concentration of a surfactant and solid particles and the residence of solid particles at the oil-water interface often being required during the synthesis of a macro-emulsion and the surface tension being reduced so as to stabilize large oil droplets are thus overcome. The development of a simple and cost-reduced method for the synthesis of an emulsion in the present invention is of great significance.
C08J 3/03 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
92.
CHROMIUM PHOSPHONATE METAL-ORGANIC FRAMEWORKS, PROCESS FOR PREPARING THE SAME AND USES THEREOF
The present application relates to metal-organic frameworks (MOFs). More specifically, the present application relates to process for their preparation and uses thereof. The present application includes a process for preparing a chromium(III) phosphonate metal-organic framework (MOF) comprising: a) dehydrating a hydrogen-bonded metal-organic framework (HMOF) comprising chromium (III) hydrogen bonded to one or more organic polyphosphonate molecule by heating the HMOF at a controlled rate; b) cooling the dehydrated HMOF from a) to provide the MOF.
C07F 9/655 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
93.
CHROMIUM PHOSPHONATE METAL-ORGANIC FRAMEWORKS, PROCESS FOR PREPARING THE SAME AND USES THEREOF
The present application relates to metal-organic frameworks (MOFs). More specifically, the present application relates to process for their preparation and uses thereof. The present application includes a process for preparing a chromium(III) phosphonate metal-organic framework (MOF) comprising: a) dehydrating a hydrogen-bonded metal-organic framework (HMOF) comprising chromium (III) hydrogen bonded to one or more organic polyphosphonate molecule by heating the HMOF at a controlled rate; b) cooling the dehydrated HMOF from a) to provide the MOF.
C07F 9/655 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
94.
METHODS OF REDUCING SYMPTOMS OF OPIOID WITHDRAWAL SYNDROME AND RISK OF RELAPSE TO DRUG SEEKING
Methods of reducing symptoms of opioid withdrawal syndrome and risk of relapse to drug seeking are provided. The method comprises administering to the subject an effective amount of probenecid.
A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compound, a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an active ingredient.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
Described herein are non-classical MHC-nanoparticle complexes that expand invariant NKT cells. Expansion of invariant NKT cells are useful in the treatment of autoimmune or inflammatory disorders
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07K 14/74 - Major histocompatibility complex [MHC]
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
97.
METFORMIN PREVENTS HYPERGLYCAEMIA-ASSOCIATED, OXIDATIVE STRESS-INDUCED VASCULAR ENDOTHELIAL DYSFUNCTION: ESSENTIAL ROLE FOR THE ORPHAN NUCLEAR RECEPTOR, NR4A1 (NUR77)
Metformin prevents hyperglycaemia-associated, oxidative stress-induced vascular endothelial dysfunction at low concentrations (~1 µM). The orphan nuclear receptor Nr4al (i.e. Nur77) is involved in the protective activity, which can be reversed by a Na4rl antagonist.
Methods of treating and/or preventing dysfunctions associated with Alzheimer's Disease such as memory loss, hippocampal long-term potentiation impairment, neuronal hyperactivity, and neuronal cell death using R-carvedilol, a metabolite thereof, and/or a salt thereof. Also described are related uses and pharmaceutical compositions.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Methods of treating and/or preventing dysfunctions associated with Alzheimer's Disease such as memory loss, hippocampal long-term potentiation impairment, neuronal hyperactivity, and neuronal cell death using R-carvedilol, a metabolite thereof, and/or a salt thereof. Also described are related uses and pharmaceutical compositions.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
